JIXING is a leading biotechnology company headquartered in Shanghai committed to bringing innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases.
Backed by RTW Investments, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, industry leading talent, and patient-centric focus, JIXING is dedicated to deliver a meaningful and lasting impact on patients in Greater China.
Roderick Wong, MD
Roderick Wong, MD, is Chairman and Board Executive Director of JIXING. He also serves as Managing Partner and Chief Investment Officer of RTW Investments, LP (“RTW”). Rod is responsible for managing the firm’s investments focused on innovative drug development. Prior to forming RTW, he was a Managing Director and sole Portfolio Manager for the Davidson Kempner Healthcare Funds.
Before joining Davidson Kempner, Rod held various healthcare investment and research roles at Sigma Capital Partners and Cowen & Company.
Rod simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.
Rod has a keen interest in educating the next generation of life science entrepreneurs. He regularly sits on a variety of corporate boards. In addition, he serves on the board of Penn Medicine, as an Adjunct Associate Professor of Finance at NYU Stern, and as Chairman of the RTW Charitable Foundation.
Peter Fong, PhD
Peter Fong, PhD, serves on JIXING’s board of directors and Chief Executive Officer. He previously served as the founding Chief Executive Officer of JIXING during the company’s formation in 2019/2020. He is also a Senior Managing Director, Head of Company Creation at RTW Investments, LP (“RTW”).
Prior to joining RTW, Peter worked at Flagship Pioneering as a member of the innovation team. In this role, he oversaw the creation and financing of four Flagship companies. Peter also worked at Genentech in Business Development, where he led multiple transactions, including the company’s partnership with BioNTech on their mRNA personalized cancer vaccine. Before Genentech, Peter led the company creation efforts at Memorial Sloan Kettering Cancer Center and co-founded Carigent Therapeutics.
Peter received a PhD degree in bioengineering from Yale University, where he subsequently was a Brown-Coxe Postdoctoral Fellow, and his BS in biochemistry from Indiana University.
Joseph Romanelli previously served as Board Executive Director and Chief Executive Officer, having led JIXING from July 2021 to June 2022. Joseph will continue to serve as a member of JIXING’s Board of Directors after June 2022.
Joseph has more than 25 years of biopharmaceutical and biotechnology experience, nearly all with Merck & Co., Inc. (“Merck” or “MSD”). He will lead Human Health International and join Merck’s Executive Team, effective August 1, 2022. Most recently, he served as the President of MSD China for more than four years, where he oversaw over 20 product launches, including Keytruda and Gardasil, the latter becoming the largest multinational company (MNC) product in China by revenue. Due to the outstanding product launches and industry leading growth, MSD grew from the 7th in 2017 to the 2nd largest MNC in 2020 in China by revenue under his leadership. From an industry and organizational perspective, he was named a “Top Ten Pharma Leader of the Year” in 2019 by the National Healthy China Forum and managed the company’s more than 5,000 employees in the market. He also briefly served as President of U.S. Human Health at Merck overseeing the company’s largest market by revenue. Previously, Joseph held senior roles, including Vice President of Investor Relations.
Joseph earned a BA in Biological Sciences from the University of Delaware and an MBA from Fordham University’s Graduate School of Business.